Invest Ophthalmol Vis Sci:市售的扫描激光眼镜在糖尿病视网膜病变的应用--视网膜血氧饱和度和血管直径测量!

2017-11-02 cuiguizhong MedSci原创

美国伊利诺伊大学眼科与视觉科学系的Blair NP近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项工作,他们用市售的扫描激光检眼镜(SLO)来辨别不同糖尿病性视网膜病变(DR)阶段的视网膜血管直径和血红蛋白氧饱和度的变化。

美国伊利诺伊大学眼科与视觉科学系的Blair NP近日在Invest Ophthalmol Vis Sci杂志上发表了他们近期的一项工作,他们用市售的扫描激光检眼镜(SLO)来辨别不同糖尿病性视网膜病变(DR)阶段的视网膜血管直径和血红蛋白氧饱和度的变化。

具体的试验方法如下:研究群体分为没有糖尿病(无DM)组、无糖尿病性视网膜病变(无DR)组、非增殖性糖尿病性视网膜病变(NPDR)组或增殖性糖尿病性视网膜病变(PDR,均具有光凝)组,对这一百八十一名受试者使用具有双激光器(532nm和633nm)的扫描激光检眼镜(SLO)进行成像。设计图像分析软件来确定视网膜动脉和静脉(DA和DV),以及视网膜中央动脉和静脉等类似血管(CRAE和CRVE)的直径。根据两个波长图像上的血管光密度估计动脉和静脉中血红蛋白(SO2A和SO2V)的氧饱和度。通过调整性别、种族、年龄、眼睛和眼底色素沉着的影响因素来做出合理的统计模型。

结果他们发现,相比没有糖尿病(无DM)组,增殖性糖尿病性视网膜病变(PDR)组的动脉视网膜中央动脉和和静脉显着减少(P≤0.03)。 静脉和视网膜中央静脉在没有糖尿病(无DM)组和无糖尿病性视网膜病变(无DR)组之间相似,但在非增殖性糖尿病性视网膜病变(NPDR)组中高于无糖尿病性视网膜病变(无DR)组(P≤0.01)。疾病阶段对SO2A的影响因种族而异,相对于没有糖尿病(无DM)组,仅在西班牙裔参与者中NPDR和PDR组中有增加(P≤0.02)。相对于没有糖尿病(无DM)组,NPDR和PDR中SO2V显着增加(P≤0.05)。

因此,他们认为,通过广泛使用扫描激光检眼镜(SLO)可以检测视网膜血管的直径和糖尿病视网膜病变中SO2的变化。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-11-04 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-11-04 oliver169
  4. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2050889, encodeId=0d2b205088956, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Wed Jul 25 11:42:00 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269966, encodeId=40b412699668b, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279694, encodeId=20dc12e969423, content=<a href='/topic/show?id=265c66e50ea' target=_blank style='color:#2F92EE;'>#激光#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66750, encryptionId=265c66e50ea, topicName=激光)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378824, encodeId=6f8a13e882487, content=<a href='/topic/show?id=63198914eed' target=_blank style='color:#2F92EE;'>#血氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89147, encryptionId=63198914eed, topicName=血氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413914, encodeId=e39d141391483, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541298, encodeId=20ad154129898, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548693, encodeId=b55d1548693c1, content=<a href='/topic/show?id=3de48914374' target=_blank style='color:#2F92EE;'>#血氧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89143, encryptionId=3de48914374, topicName=血氧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0be914108460, createdName=循证小兵, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560404, encodeId=94291560404c2, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566413, encodeId=1a361566413e5, content=<a href='/topic/show?id=4ff1e294238' target=_blank style='color:#2F92EE;'>#眼镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72942, encryptionId=4ff1e294238, topicName=眼镜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=508115130308, createdName=zhangfenasdf, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595736, encodeId=95ed1595e3602, content=<a href='/topic/show?id=c5326402609' target=_blank style='color:#2F92EE;'>#氧饱和度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64026, encryptionId=c5326402609, topicName=氧饱和度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b2d218300656, createdName=lqvr, createdTime=Sat Nov 04 13:42:00 CST 2017, time=2017-11-04, status=1, ipAttribution=)]
    2017-11-04 lqvr

相关资讯

FDA批准阿柏西普治疗DR合并DME

近日,FDA批准(Eylea)阿柏西普注射剂,可用于糖尿病黄斑水肿(DME)合并糖尿病视网膜病变(DR)的治疗。糖尿病视网膜病变(DR)是最常见糖尿病眼部疾病,是美国成年人中致盲的首要疾病。根据美国疾病控制与防范中心的调查,糖尿病(包括I型与2型)已经危及全美2900万人,在20-74岁的成人中,DR是新的最常见的致盲疾病。在2008年,有33%成年糖尿病患者在40岁或以上出现DR。在一些DR合并

JAMA Ophthalmol:富含ω-3脂肪酸的饮食可显著降低糖尿病视网膜病变的发病率

据发表于JAMA Ophthalmol的一项前瞻性观察研究显示,摄入ω3脂肪酸的老年2型糖尿病患者与食用两星期鱼油效果一样可显著降低糖尿病视网膜病变的发病风险。 糖尿病视网膜病变是导致老年人视力丧失的主要原因。其发病机制尚不完全清楚,但炎症、氧化应激和微血管改变在视网膜功能恶化中起着重要作用。视网膜中长链ω3多不饱和脂肪酸的含量很高,而长链ω3多不饱和脂肪酸形成oxylipins,具有抗炎和

Br J Ophthalmol:糖尿病视网膜病变的早期指标-视网膜动脉壁厚度

糖尿病视网膜病变(DR)是一种致盲率很高的疾病,而且该类患者正在逐渐增多。为了预防糖尿病的这种微血管并发症,很多学会提出了不少预防措施,包括控制血糖、糖化血红蛋白以及血压等。一般来说,DR是一种高血糖导致的新陈代谢紊乱的病变,会增加血管基底膜成分的合成和积累,并导致基底膜的增厚。但是这些早期的变化并不能被我们常规的眼底检查发现,如果我们能在DR出现临床症状前通过直接可视化和非侵入性的手段来及早发现

Telemed J E Health. :患者家庭开车到眼科医生办公室的时间对糖尿病视网膜病变筛查的影响!

法国马赛大学的Macon C近日在Telemed J E Health杂志上发表了他们的一项很有趣的工作,他们研究了开汽车到最近眼科医生的时间对筛查糖尿病视网膜病变(DR)的影响,他们发现,距离最近眼科医生开车时间越长,糖尿病患者筛查出患糖尿病视网膜病变(DR)的时间也越长。

PLoS One:血清高甘露糖结合凝集素的水平与国人2型糖尿病患者糖尿病视网膜病变有关

PLoS One:血清高甘露糖结合凝集素的水平与国人2型糖尿病患者糖尿病视网膜病变有关该研究的目的是为了探究伴或不伴糖尿病视网膜病变(DR)的2型糖尿病患者血清中甘露糖结合凝集素(MBL)的水平。测定324名2型糖尿病患者以及300名健康对照者血清中MBL的水平。采用多元回归模型进行多因素分析。使用接受者操作特性曲线测试MBL以及其他标志物的总体预测精确度。结果发现,伴DR的糖尿病患者以及伴威胁视

Vision Res. :糖尿病视网膜病变,代谢记忆和表观遗传修饰

底特律韦恩州立大学Kresge眼科研究所的Kowluru RA教授在近期的Vision Res杂志上发表了一项工作,对糖尿病视网膜病变中代谢记忆和表观遗传修饰现象进行了讨论。